Prof. Dr. Katja Zeppenfeld, MD, PhD, FESC, FEHRA is a board-certified internist, cardiologist, full professor in cardiac electrophysiology and head of the clinical electrophysiology unit of the Heart Center Leiden.
Dr. Zeppenfeld received her medical degree from the University of Bochum, Germany, where she completed her internal medicine residency and cardiology fellowship. After completion of her PhD and research fellowships in the United Kingdom and the United States of America she continued her clinical and academic work at the Leiden University Medical Centre, the Netherlands.
Her clinical interests include diagnosis and treatment of complex cardiac arrhythmias with a particular focus on catheter ablation of ventricular tachycardiaand arrhythmias in patients with congenital heart disease.
Her research focuses on defining the substrate of arrhythmias in patients with structural heart disease and GUCH patients and on developing novel methods and applications for substrate imaging and multimodal image integration.
Role of VT Ablation in patients with Tetralogy of Fallot
Ventricular arrhythmias are an important cause for late morbidity and sudden cardiac death in the growing population of adults with repaired congenital heart disease. Therapeutic interventions depend on the type of VA, which can be polymorphic ventricular tachycardia or ventricular fibrillation in patients without ventricular scars but also potentially fatal monomorphic re-entrant VTs, typical for patients with ventricular scars or obstacles. Advances in surgical techniques have improved survival and have important implications for the arrhythmia substrates and prognosis. Over the last decades progress has been made to determine the anatomical basis for monomorphic VT in patients with ventricular surgical scars and patch material. These substrates can be currently identified by electroanatomical mapping and targeted during sinus rhythm by radiofrequency catheter or surgical ablation without the need for VT induction. A review of the changing VA substrates, the potential consequences for substrate tailored treatment and endpoints of ablation will be provided.